Enhanced molecular dynamics sampling of drug target conformations.
Atlanta, United States. In Biopolymers, Jan 2016
RaMD-db is shown to be able to generate a broad distribution of structures of a drug target, Cyclophilin A. These structures that have never been observed previously in very long conventional MD can be further used for structure-based computer-aided drug discovery, and docking, and thus, in the identification and design of potential novel inhibitors.
Cyclophilin polymorphism and virus infection.
Hannover, Germany. In Curr Opin Virol, Oct 2015
Several coding and non-coding genetic variants in the PPIA gene encoding for CypA have been described, but there is only limited information about their influence on the course of viral infection.
[Novel methods of hepatitis C treatment and prevention].
Laizhou, China. In Postepy Hig Med Dosw (online), 2014
Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA - miR-122).
Making sense of HIV innate sensing.
Baltimore, United States. In Immunity, 2014
In this issue of Immunity, Lahaye et al. (2013) demonstrate that HIV capsid-cyclophilin A interactions affect viral cDNA sensing by the DNA sensor cCAS and contribute to differential pathogenesis of HIV-1 and HIV-2.
HIV-1 evades innate immune recognition through specific cofactor recruitment.
London, United Kingdom. In Nature, 2013
Here we show that HIV-1 capsid mutants N74D and P90A, which are impaired for interaction with cofactors cleavage and polyadenylation specificity factor subunit 6 (CPSF6) and cyclophilins (Nup358 and CypA), respectively, cannot replicate in primary human monocyte-derived macrophages because they trigger innate sensors leading to nuclear translocation of NF-κB and IRF3, the production of soluble type 1 IFN and induction of an antiviral state.